In a patient receiving first‑line anti‑tuberculosis therapy (isoniazid, rifampicin, pyrazinamide, ethambutol) who develops a generalized rash, what is the underlying pathology and what is the recommended management algorithm for drug discontinuation and stepwise re‑introduction?

Management of Generalized Rash During HRZE Therapy

Stop all anti-tuberculosis drugs immediately when a generalized rash develops, then systematically reintroduce drugs one at a time starting with isoniazid, followed by rifampicin, and finally pyrazinamide (if needed), with each drug given at low doses initially and escalated over 2-3 days while monitoring for recurrence. 1

Underlying Pathology

The generalized rash represents a hypersensitivity reaction that can manifest as:

• Morbilliform (maculopapular) rash (most common, 72.3% of cases) 2
• Urticaria (8.5% of cases) 2
• Erythema multiforme syndrome (8.5% of cases) 2
• Less commonly: exfoliative dermatitis, lichenoid eruptions, or DRESS syndrome 2, 3

Pyrazinamide is the most common offending drug (2.38% incidence), followed by streptomycin (1.45%), ethambutol (1.44%), rifampicin (1.23%), and isoniazid (0.98%). 2 However, 97% of cutaneous reactions occur within the first 2 months of treatment initiation. 2

Immediate Management Algorithm

Step 1: Discontinue All Drugs and Assess Severity

• Stop rifampicin, isoniazid, pyrazinamide, and ethambutol immediately upon development of generalized rash 1

• Assess for severe cutaneous adverse reactions requiring immediate hospitalization:

  • Mucosal involvement (oral, ocular, genital)
  • Blistering or skin detachment (suggesting Stevens-Johnson syndrome/TEN)
  • Facial edema or angioedema
  • Systemic symptoms: fever >38.5°C, lymphadenopathy, hepatosplenomegaly
  • Eosinophilia >1000/µL or >10% (suggesting DRESS syndrome) 3

• If severe features are present: Discontinue the drug permanently and do not attempt rechallenge 4

• If mild-moderate rash without systemic features: Proceed with bridge therapy and rechallenge protocol 1

Step 2: Bridge Therapy During Recovery Phase

• For infectious/smear-positive TB or clinically unwell patients: Initiate streptomycin plus ethambutol as temporary bridge therapy until rash resolves completely 1
• For stable, non-infectious TB: No treatment required during recovery phase 1
• Wait for complete resolution of rash and normalization of any laboratory abnormalities (eosinophil count, liver enzymes) before starting rechallenge 1

Sequential Drug Reintroduction Protocol

Critical principle: Reintroduce drugs one at a time with escalating doses, monitoring for 2-3 days at each step before adding the next drug. Never use fixed-dose combinations during rechallenge. 1

Phase 1: Isoniazid Reintroduction (Days 1-6)

• Day 1-2: Start isoniazid 50 mg once daily 1
• Day 3-6: If no reaction, increase to 300 mg once daily (full dose) 1
• Monitor daily for:
  • Rash recurrence
  • Fever, malaise
  • Hepatic symptoms (nausea, vomiting, jaundice)

Phase 2: Rifampicin Reintroduction (Days 7-15)

• Day 7-9: Add rifampicin 75 mg once daily (continue full-dose isoniazid) 1
• Day 10-12: If no reaction, increase rifampicin to 300 mg once daily 1
• Day 13-15: Increase to full dose:
  • 450 mg daily if patient <50 kg
  • 600 mg daily if patient ≥50 kg 1

Phase 3: Pyrazinamide Reintroduction (Days 16-24) - If Needed

Important caveat: Pyrazinamide should NOT be reintroduced if the initial rash occurred >1 month after treatment initiation, as late-onset pyrazinamide reactions carry poor prognosis. 1

• Day 16-18: Add pyrazinamide 250 mg once daily (continue full-dose isoniazid + rifampicin) 1
• Day 19-21: If no reaction, increase to 1.0 g once daily 1
• Day 22-24: Increase to full dose:
  • 1.5 g daily if patient <50 kg
  • 2.0 g daily if patient ≥50 kg 1

Phase 4: Ethambutol Reintroduction (If Needed)

• If rash recurs during pyrazinamide rechallenge, ethambutol can be substituted 1
• Start at 15 mg/kg daily and monitor for 3 days before declaring tolerance 5

Management of Rechallenge Failure

If Rash Recurs During Isoniazid Rechallenge:

• Discontinue isoniazid permanently 1
• Use alternative regimen: Rifampicin + ethambutol + fluoroquinolone (levofloxacin or moxifloxacin) for 18-24 months 1

If Rash Recurs During Rifampicin Rechallenge:

• Discontinue rifampicin permanently 1
• Use alternative regimen: Isoniazid + ethambutol + fluoroquinolone for 18-24 months 1

If Rash Recurs During Pyrazinamide Rechallenge:

• Discontinue pyrazinamide permanently 1, 6
• Use alternative regimen: Isoniazid + rifampicin + ethambutol for 2 months, then isoniazid + rifampicin for 7 months (total 9 months) 1, 6

Special Monitoring During Rechallenge

• Daily clinical assessment for rash, fever, malaise, or systemic symptoms 1
• Baseline and weekly liver function tests (AST, ALT, bilirubin) during the first 2 weeks of each drug addition, then every 2 weeks for 2 months 1
• Complete blood count with differential if DRESS syndrome was suspected initially (monitor eosinophil count) 3
• Visual acuity testing before ethambutol reintroduction and monthly thereafter 5

Critical Pitfalls to Avoid

1. Do not rechallenge if the initial reaction included:

   • Mucosal involvement or blistering (Stevens-Johnson syndrome/TEN)
   • Shock, acute renal failure, or thrombocytopenic purpura with rifampicin 5
   • Hepatic decompensation (ascites, encephalopathy) 1
   • DRESS syndrome with multi-organ involvement 3

2. Do not use fixed-dose combinations (Rifater, Rifinah) during rechallenge, as this prevents identification of the culprit drug 1

3. Do not reintroduce pyrazinamide if the initial reaction occurred >1 month after treatment start, as late-onset pyrazinamide hepatotoxicity has poor prognosis 1

4. Do not confuse pyrazinamide-induced flushing with true allergic reaction—flushing is benign and does not require drug discontinuation 7

5. Female patients have 4-fold higher risk of immediate hypersensitivity reactions (OR 4.085), requiring heightened vigilance 8

6. HIV-positive patients have significantly higher rates of cutaneous reactions (27.7% of CADR cases) and may require more cautious rechallenge 2

Alternative Rapid Rechallenge Protocol (For Research Context)

A 6-8 step graded challenge protocol has been successfully used in research settings for immediate-type hypersensitivity reactions, with doses escalated every 30-60 minutes under close observation. 8 However, this approach should only be attempted in hospital settings with resuscitation capabilities and is not recommended for routine clinical practice. 8